Altimmune (3G0) Price & Analysis

8 Followers

3G0 Stock Chart & Stats

€2.64

€0.03(1.25%)

At close: Jul 24 4:00 PM EDT

€2.64

€0.03(1.25%)

Day’s Range― - ―

52-Week Range€2.20 - €5.32

Previous CloseN/A

Volume0.00

Average Volume (3M)156.00

Market Cap

€510.00M

Enterprise Value€273.45

Total Cash (Recent Filing)€326.32M

Total Debt (Recent Filing)€35.75M

Price to Earnings (P/E)―

Beta0.72

Next Earnings

Nov 10, 2026

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.78

Shares Outstanding194,517,700

10 Day Avg. Volume70

30 Day Avg. Volume156

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)1.41

Price to Sales (P/S)7757.46

P/FCF Ratio-4.71

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€16.76

Price Target Upside534.92% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-0.51

Revenue Forecast (FY)€1.65K

Bulls Say, Bears Say

Bulls Say

Strong Capitalization And RunwayThe $519M cash balance and low leverage provide meaningful funding capacity for the lead MASH program. Management’s stated runway through the 52-week readout reduces near-term financing pressure and supports continued clinical execution over the next several years.

MASH Program Advanced To Phase IIIInitiating a large global Phase III trial is a significant development milestone that can increase the commercial relevance of pemvidutide if efficacy and safety are confirmed. Broad international enrollment also establishes an operational foundation for potential regulatory filings.

Promising AUD Clinical DifferentiationRECLAIM’s positive results across clinical endpoints and the objective PEth biomarker suggest pemvidutide may address both alcohol use and associated metabolic burden. This broader profile could support differentiation in AUD and liver-disease treatment if replicated in pivotal testing.

Bears Say

Pre-commercial Revenue And Persistent LossesAltimmune remains dependent on clinical development rather than product sales, with negligible revenue far below its operating cost base. The large recurring loss indicates that profitability is not yet supported by the business model and will remain dependent on successful development or external funding.

Cash Burn And AUD Funding GapSustained operating cash burn reduces financial flexibility even after the recent capital raise. Because management says the current runway excludes a potential AUD Phase III, advancing that opportunity may require debt, royalties, partnerships, or further financing that is not assured.

Clinical Execution And Tolerability RisksGastrointestinal discontinuations could constrain dose optimization, adherence, or the treatment’s eventual risk-benefit profile. At the same time, competition among MASH Phase III programs may increase enrollment costs and complicate execution, making timely development less certain.

Altimmune News

Altimmune price target lowered to $17 from $18 at Evercore ISI

Evercore ISI analyst Michael DiFiore lowered the firm’s price target on Altimmune (ALT) to $17 from $18 and...

8d ago

ALT

3 Under $10 Stocks With 150%+ Upside to Buy in September 2026, According to Analysts

Some low‑priced stocks have the potential to offer solid upside backed by clear catalysts. In September, three names...

30d ago

ALT

KDK

Altimmune Appoints Richard Menziuso as Principal Accounting Officer

The latest update is out from Altimmune ( ($ALT) ). On September 24, 2026, Altimmune’s Board of Directors...

2d ago

ALT

Altimmune’s Phase 3 MASH Trial Puts Pemvidutide in the Spotlight for Investors

Altimmune ($ALT) announced an update on their ongoing clinical study. Altimmune, Inc. has launched a major Phase 3...

8d ago

ALT

Altimmune Charts Long Runway with Bold Trial Push

Altimmune (($ALT)) has held its Q2 earnings call. Read on for the main highlights of the call. Altimmune’s...

1M ago

ALT

Altimmune Maintained at Buy as Late-Stage Liver Programs Advance and $20 Price Target Remains Unchanged

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Altimmune. The associated price target remains...

2M ago

ALT

Altimmune reports Q2 EPS (12c), consensus (12c)

“We have achieved several important milestones as we continue to successfully execute our strategy, including the initiation of...

2M ago

ALT

Marathon, Phillips 66, Clean Energy Fuels, Altimmune, Eaton Insider Shake‑Up

Insiders have been trading these 5 stocks: (($MPC)), (($PSX)), (($CLNE)), (($ALT)) and (($ETN)). Here is a breakdown of...

2M ago

ALT

ETN

Is ALT a Buy, Before Earnings?

Altimmune (ALT) is scheduled to report 2nd quarter earnings on 08/12/2026. Regarding Q2 estimates, Wall Street analysts expect...

2M ago

ALT

ALT Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Altimmune (ALT) is scheduled to report 2nd quarter earnings on 08/06/2026. Regarding Q2 estimates, Wall Street analysts expect...

2M ago

ALT

Altimmune initiates PERFORMA trial

Altimmune (ALT) announced that the company has begun enrolling patients in the PERFORMA Phase 3 trial evaluating the...

2M ago

ALT

Altimmune’s RECLAIM Study Adds an Addiction Angle to Its Obesity Drug

Altimmune ($ALT) announced an update on their ongoing clinical study. Altimmune’s RECLAIM study looks at whether its drug...

2M ago

ALT

Barclays says trial data highlights meaningful opportunity for Altimmune in AUD

Barclays analyst Eliana Merle notes Altimmune (ALT) reported topline data from the Phase 2 RECLAIM trial of pemvidutide...

2M ago

ALT

H.C. Wainwright sees ‘clear Phase 2 win’ for Altimmune

H.C. Wainwright reiterates a Buy rating on Altimmune (ALT) with a $20 price target saying the company announced...

2M ago

ALT

3G0 FAQ

What was Altimmune Inc’s price range in the past 12 months?

Altimmune Inc lowest stock price was €2.20 and its highest was €5.32 in the past 12 months.

What is Altimmune Inc’s market cap?

Altimmune Inc’s market cap is €510.00M.

When is Altimmune Inc’s upcoming earnings report date?

Altimmune Inc’s upcoming earnings report date is Nov 10, 2026 which is in 40 days.

How were Altimmune Inc’s earnings last quarter?

Altimmune Inc released its earnings results on Aug 12, 2026. The company reported -€0.106 earnings per share for the quarter, beating the consensus estimate of -€0.122 by €0.016.

Is Altimmune Inc overvalued?

According to Wall Street analysts Altimmune Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Altimmune Inc pay dividends?

Altimmune Inc does not currently pay dividends.

What is Altimmune Inc’s EPS estimate?

Altimmune Inc’s EPS estimate is -0.12.

How many shares outstanding does Altimmune Inc have?

Altimmune Inc has 194,517,700 shares outstanding.

What happened to Altimmune Inc’s price movement after its last earnings report?

Altimmune Inc reported an EPS of -€0.106 in its last earnings report, beating expectations of -€0.122. Following the earnings report the stock price went up 0.385%.

Which hedge fund is a major shareholder of Altimmune Inc?

Currently, no hedge funds are holding shares in DE:3G0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Altimmune Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

176.97%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Altimmune Inc

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.

Altimmune (3G0) Earnings & Revenues

Historic Earnings Reports

3G0 Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed substantial clinical and operational momentum: initiation of a global Phase III in MASH, robust positive Phase II AUD data that met multiple registrational endpoints (including objective biomarker improvements and 9.1% weight loss), completed enrollment in ALD, and a strengthened balance sheet ($519M cash). Key positives notably outweigh near‑term risks, though important caveats remain — including higher operating expenses, GI-related tolerability signals under further review, a competitive MASH enrollment landscape, and the need to secure non-dilutive funding for a potential AUD Phase III (not covered by the current runway). Several pivotal readouts (RESTORE H2 2027, PERFORMA 52‑week in 2029) and regulatory engagements are upcoming and will be determinative for long-term value.View all DE:3G0 earnings summaries

3G0 Stock 12 Month Forecast

Average Price Target

€16.76

▲(534.92% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","7":"€7","13":"€13","19":"€19","25":"€25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24.7015958,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€24.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.76179715,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€16.76</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.8219985,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€8.82</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7,13,19,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.62,4.318584292307692,6.017168584615384,7.7157528769230765,9.41433716923077,11.112921461538463,12.811505753846152,14.510090046153845,16.208674338461538,17.90725863076923,19.605842923076924,21.304427215384614,23.003011507692307,{"y":24.7015958,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.62,3.7078305499999997,4.7956611,5.88349165,6.9713221999999995,8.059152749999999,9.146983299999999,10.234813849999998,11.322644399999998,12.410474949999998,13.498305499999997,14.586136049999997,15.6739666,{"y":16.76179715,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.62,3.0970768076923076,3.574153615384615,4.051230423076923,4.528307230769231,5.005384038461538,5.482460846153846,5.959537653846153,6.436614461538461,6.913691269230769,7.390768076923076,7.867844884615384,8.344921692307693,{"y":8.8219985,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.28,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.35,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.466,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.296,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.021,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.82,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.639,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.597,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.585,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >